Theravance Biopharma Inc (TBPH)
9.38
-0.09
(-0.95%)
USD |
NASDAQ |
May 10, 16:00
9.38
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Total Assets (Quarterly): 382.00M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 382.00M |
| September 30, 2023 | 413.59M |
| June 30, 2023 | 446.63M |
| March 31, 2023 | 538.55M |
| December 31, 2022 | 607.40M |
| September 30, 2022 | 763.50M |
| June 30, 2022 | 360.76M |
| March 31, 2022 | 355.36M |
| December 31, 2021 | 374.82M |
| September 30, 2021 | 403.11M |
| June 30, 2021 | 429.25M |
| March 31, 2021 | 375.11M |
| December 31, 2020 | 469.06M |
| September 30, 2020 | 512.19M |
| June 30, 2020 | 564.33M |
| March 31, 2020 | 605.41M |
| December 31, 2019 | 408.83M |
| September 30, 2019 | 445.34M |
| June 30, 2019 | 492.45M |
| March 31, 2019 | 531.26M |
| December 31, 2018 | 560.24M |
| Date | Value |
|---|---|
| September 30, 2018 | 370.96M |
| June 30, 2018 | 421.36M |
| March 31, 2018 | 480.11M |
| December 31, 2017 | 441.40M |
| September 30, 2017 | 486.16M |
| June 30, 2017 | 543.89M |
| March 31, 2017 | 588.04M |
| December 31, 2016 | 639.25M |
| September 30, 2016 | 356.29M |
| June 30, 2016 | 374.49M |
| March 31, 2016 | 293.12M |
| December 31, 2015 | 300.12M |
| September 30, 2015 | 257.51M |
| June 30, 2015 | 289.48M |
| March 31, 2015 | 324.90M |
| December 31, 2014 | 337.77M |
| September 30, 2014 | 381.70M |
| June 30, 2014 | 430.59M |
| March 31, 2014 | 26.17M |
| December 31, 2013 | 25.18M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
355.36M
Minimum
Mar 2022
763.50M
Maximum
Sep 2022
470.93M
Average
445.34M
Median
Sep 2019
Total Assets (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 655.94M |
| Nektar Therapeutics | 398.03M |
| Vanda Pharmaceuticals Inc | 648.44M |
| Fate Therapeutics Inc | 506.22M |
| FibroGen Inc | 365.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 169.00M |
| Shareholders Equity (Quarterly) | 213.00M |
| Current Ratio | 5.392 |